Skip to main content

20.06.2020 | Letter | Ausgabe 8/2020 Open Access

Advances in Therapy 8/2020

Letter to the Editor Regarding “Impact of Chloroprocaine on the Eligibility for Hospital Discharge in Patients Requiring Ambulatory Surgery Under Spinal Anesthesia: An Observational Multicenter Prospective Study”

Advances in Therapy > Ausgabe 8/2020
Elsbeth J. Wesselink, Marcel A. de Leeuw
Wichtige Hinweise

Digital Features

To view digital features for this article go to https://​doi.​org/​10.​6084/​m9.​figshare.​12459125.
We read with considerable interest the article by Capdevila and colleagues concerning the impact of chloroprocaine on the eligibility for hospital discharge in patients requiring ambulatory surgery under spinal anesthesia [ 1]. We encourage the analysis of spinal chloroprocaine anesthesia as a possible alternative for spinal lidocaine anesthesia and therefore congratulate the authors on this publication. We would like to make a few comments regarding the primary outcomes.
The hospital discharge in this observational multicenter prospective study was 256.6 ± 80.7 min (mean ± SD)/median 245.0 (range 90–538) min for orthopedic procedures under spinal anesthesia with chloroprocaine. The most common dose of chloroprocaine administered spinally was 50 mg (59.2%), then 40 mg (32.3%). We recently conducted a double-blind randomized trial comparing 40 mg chloroprocaine with 40 mg prilocaine for spinal anesthesia in ambulatory knee arthroscopy [ 2]. Using exactly the same discharge criteria, we found that the time from injection to eligibility for hospital discharge in the chloroprocaine arm (40 mg) in our study was substantial shorter, i.e., 222 ± 72 min (mean ± SD). The use of different dosages of spinal anesthesia using chloroprocaine resulting in different hospital discharge times suggests a possible correlation and therefore we recommend that the authors perform a subgroup analysis (40 mg/50 mg chloroprocaine) to analyze this phenomenon within their cohort.
Furthermore, there was a similarity in effectiveness of spinal anesthesia using 40 mg chloroprocaine in our study compared to 40 mg (32.3%)/50 mg (59.2%) in Capdevila et al.’s cohort. We reported a success rate of spinal anesthesia in the chloroprocaine arm of 97.3%. Capdevila reported a success rate of 95.6% in the orthopedic cohort. This lack of difference in effectiveness may indicate that 40 mg should be an adequate dose for spinal anesthesia in ambulatory orthopedic surgery.
Finally, there was a substantial difference in the administration of vasoactive agents (10% in Capdevila’s cohort compared to 22.7% in the chloroprocaine arm of our cohort). Whether this could be explained by a slightly higher peak sensory block (T9) with therefore more hemodynamic consequences in the chloroprocaine arm of our cohort compared to Capdevila’s cohort (peak sensory block T10) remains questionable. This could be the result of different standard operating procedures regarding the use of vasopressor agents.
We strongly agree with the authors that chloroprocaine is a short-acting local anesthetic particularly suitable for short surgical procedures and to ambulatory management.



No funding or sponsorship was received for publication of this letter by any of the authors.


All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.


Elsbeth J Wesselink and Marcel A de Leeuw have nothing to disclose.

Compliance with Ethics Guidelines

This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Data Availability

Data sharing is not applicable to this article as no datasets were generated or analyzed.

Open Access

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by-nc/​4.​0/​.

Unsere Produktempfehlungen

e.Med Interdisziplinär


Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf

Alle e.Med Abos bis 30. April 2021 zum halben Preis!

Jetzt e.Med zum Sonderpreis bestellen!

e.Med Innere Medizin


Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

e.Med Allgemeinmedizin


Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.

Über diesen Artikel

Weitere Artikel der Ausgabe 8/2020

Advances in Therapy 8/2020 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin